(RTTNews) – In today’s trading session, several leading biotechnology names delivered notable gains, fueled by key clinical updates and strategic milestones.
Can-Fite Soars on Pancreatic Cancer Data
Can-Fite BioPharma Ltd. (CANF) surged over 55% following a positive Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma. The trial met its primary safety endpoint and demonstrated durable overall survival outcomes. Building on these findings, Can-Fite plans to advance Namodenoson into a Phase 2b combination study with chemotherapy.
CANF closed at $4.63, up 55.89%.
SeaStar Medical Hits 30% Gain
SeaStar Medical Holding Corp. (ICU) climbed more than 30% in a bid driven by revenue growth, though no new announcement underpinned the rise. Its flagship therapy, QUELIMMUNE (SCD‑PED), received FDA approval in 2024 for an ultra‑rare, life‑threatening form of acute kidney injury in critically ill pediatric patients.
For the quarter ended March 31, 2026, SeaStar reported net revenue of about $0.5 million, up from $0.3 million in the same period a year earlier. The company projects net product revenue of roughly $2 million for 2026, a rise from $1.2 million in 2025.
ICU closed at $4.86, up 32.43%.
Elicio Therapeutics Refines Phase 3 Plans
Elicio Therapeutics Inc. (ELTX) experienced a 31% rally on a Wednesday that included its recent inclusion in the Russell 2000 and Russell 3000 indexes. The company’s lead candidate, ELI‑002, was evaluated in the Phase 2 AMPLIFY‑7P trial for mKRAS‑driven pancreatic cancer. While the primary endpoint of disease‑free survival was missed, early treatment benefit was observed in landmark analyses. Drawing on these insights, Elicio has adjusted its Phase 3 strategy and plans to initiate a new Phase 3 trial pending funding.
ELTX closed at $5.14, up 31.46%.
Regentis Biomaterials Prepares for European Rollout of GelrinC
Regentis Biomaterials Ltd. (RGNT) advanced more than 29% without new headlines. The company’s lead product, GelrinC, is a ready‑to‑use, cell‑free hydrogel implant for repairing damaged knee cartilage. With CE Mark approval secured, Regentis will commence surgeon‑training activities in Europe this quarter to support a commercial launch later in the year.
RGNT closed at $4.57, up 29.46%.
TransCode Gains Momentum
TransCode Therapeutics Inc. (RNAZ) continued a two‑day surge, rising more than 20% on a Wednesday that saw no fresh developments. The company’s TTX‑MC138, a targeted therapy for metastatic cancer, has entered a Phase 2a trial focused on patients with circulating tumor DNA‑positive colorectal cancer following curative‑intent treatment. Enrollment will target up to 45 patients, with preliminary results expected in Q4 2026.
RNAZ closed at $7.65, up 23.19%.
Outset Medical Draws Investor Interest
Outset Medical Inc. (OM) climbed roughly 18% on a Wednesday with no new press release. The company reported first‑quarter revenue of $27.9 million in March 2026, a modest 6% decline from $29.8 million in the same period a year earlier. For the full year, Outset projects revenue between $125 million and $130 million, marking a 5%–9% increase over 2025’s $119.5 million.
OM closed at $5.10, up 18.06%.
